Gestational Trophoblastic Disease Market Research Report Information By Type (Hydatidiform Mole, Choriocarcinoma, Placental-Site Trophoblastic Tumor, and Others), by Treatment (Surgery, Suction Dilation and Curettage, and Others), by End User—Forecast Till 2032

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Gestational Trophoblastic Disease Market, by Type

6.1 Introduction

6.2 Hydatidiform mole

6.2.1 Complete

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.2.2 Partial

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.3.3 Invasive

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.3 Choriocarcinoma

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.4 Placental-site trophoblastic tumor

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.5 Epithelioid trophoblastic tumor

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.6 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 7. Global Gestational Trophoblastic Disease Market, by Treatment

7.1 Introduction

7.2 Surgery

7.2.1 Abdominal hysterectomy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.2.2 Vaginal hysterectomy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3 Chemotherapy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.4 Suction dilation and curettage (D&C)

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.5 Radiation Therapy

7.5.1 External beam radiation therapy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 8. Global Gestational Trophoblastic Disease Market, by End-user

8.1 Hospitals and Clinics

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.2 Diagnostic Centers

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.3 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 9. Global Gestational Trophoblastic Disease Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia-Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 South Korea

9.4.6 Rest of Asia-Pacific

9.5 Middle East & Africa

9.5.1 Middle East

9.5.2 Africa

Chapter 10. Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

Chapter 11. Company Profiles

11.1 Teva Pharmaceutical Industries Ltd.

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials Overview

11.1.4 Key Developments

11.1.5 SWOT Analysis

11.2 Hikma Pharmaceuticals PLC

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Pfizer Inc.

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Bristol-Myers Squibb Company

11.4.1 Company Overview

11.4.2 Product Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Antares Pharma

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 Mylan N.V.

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 Novartis AG

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financial Overview

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 BP Pharmaceuticals Laboratories Company

11.8.1 Overview

11.8.2 Product Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.9 Fresenius Kabi AG

11.9.1 Overview

11.9.2 Product Overview

11.9.3 Financials

11.9.4 Key Developments

11.9.5 SWOT Analysis

11.10 Accord Healthcare, Inc.

11.10.1 Overview

11.10.2 Product Overview

11.10.3 Financials

11.10.4 Key Developments

11.10.5 SWOT Analysis

11.11 Eli Lilly and Company

11.11.1 Overview

11.11.2 Product Overview

11.11.3 Financials

11.11.4 Key Developments

11.11.5 SWOT Analysis

11.12 Sanofi

11.12.1 Overview

11.12.2 Product Overview

11.12.3 Financials

11.12.4 Key Developments

11.12.5 SWOT Analysis

11.13 Bayer AG

11.13.1 Overview

11.13.2 Product Overview

11.13.3 Financials

11.13.4 Key Developments

11.13.5 SWOT Analysis

11.14 Amgen Inc.

11.14.1 Overview

11.14.2 Product Overview

11.14.3 Financials

11.14.4 Key Developments

11.14.5 SWOT Analysis

11.15 Merck

11.15.1 Overview

11.15.2 Product Overview

11.15.3 Financials

11.15.4 Key Developments

11.15.5 SWOT Analysis

Chapter 11 MRFR Conclusion

11.1 Key Findings

11.1.1 From CEO’s Viewpoint

11.1.2 Unmet Needs of the Market

11.2 Key Companies to Watch

11.3 Predictions for the Gestational Trophoblastic Disease Industry

Chapter 12. Appendix

LIST OF TABLES

Table 1 Global Gestational Trophoblastic Disease Market Synopsis, 2020–2027

Table 2 Global Gestational Trophoblastic Disease Market Estimates and Forecast, 2020–2027 (USD Million)

Table 3 Global Gestational Trophoblastic Disease Market, by Type, 2020–2027 (USD Million)

Table 4 Global Gestational Trophoblastic Disease Market, by Treatment, 2020–2027 (USD Million)

Table 5 Global Gestational Trophoblastic Disease Market, by End-User, 2020–2027 (USD Million)

Table 6 Global Gestational Trophoblastic Disease Market, by Region, 2020–2027(USD Million)

Table 7 North America: Gestational Trophoblastic Disease Market, by Type, 2020–2027 (USD Million)

Table 8 North America: Gestational Trophoblastic Disease Market, by Treatment, 2020–2027 (USD Million)

Table 9 North America: Gestational Trophoblastic Disease Market, by End-User, 2020–2027 (USD Million)

Table 10 North America: Gestational Trophoblastic Disease Market, by Region, 2020–2027 (USD Million)

Table 11 US: Gestational Trophoblastic Disease Market, by Type, 2020–2027 (USD Million)

Table 12 US: Gestational Trophoblastic Disease Market, by Treatment, 2020–2027 (USD Million)

Table 13 US: Gestational Trophoblastic Disease Market, by End-User, 2020–2027 (USD Million)

Table 14 US: Gestational Trophoblastic Disease Market, by Region, 2020–2027 (USD Million)

Table 15 Canada: Gestational Trophoblastic Disease Market, by Type, 2020–2027 (USD Million)

Table 16 Canada: Gestational Trophoblastic Disease Market, by Treatment, 2020–2027 (USD Million)

Table 17 Canada: Gestational Trophoblastic Disease Market, by End-User, 2020–2027 (USD Million)

Table 18 Canada: Gestational Trophoblastic Disease Market, by Region, 2020–2027 (USD Million)

Table 19 South America: Gestational Trophoblastic Disease Market, by Type, 2020–2027 (USD Million)

Table 20 South America: Gestational Trophoblastic Disease Market, by Treatment, 2020–2027 (USD Million)

Table 21 South America: Gestational Trophoblastic Disease Market, by End-User, 2020–2027 (USD Million)

Table 22 South America: Gestational Trophoblastic Disease Market, by Region, 2020–2027 (USD Million)

Table 23 Europe: Gestational Trophoblastic Disease Market, by Type, 2020–2027 (USD Million)

Table 24 Europe: Gestational Trophoblastic Disease Market, by Treatment, 2020–2027 (USD Million)

Table 25 Europe: Gestational Trophoblastic Disease Market, by End-User, 2020–2027 (USD Million)

Table 26 Europe: Gestational Trophoblastic Disease Market, by Region, 2020–2027 (USD Million)

Table 27 Western Europe: Gestational Trophoblastic Disease Market, by Type, 2020–2027 (USD Million)

Table 28 Western Europe: Gestational Trophoblastic Disease Market, by Treatment, 2020–2027 (USD Million)

Table 29 Western Europe: Gestational Trophoblastic Disease Market, by End-User, 2020–2027 (USD Million)

Table 30 Western Europe: Gestational Trophoblastic Disease Market, by Region, 2020–2027 (USD Million)

Table 31 Eastern Europe: Gestational Trophoblastic Disease Market, by Type, 2020–2027 (USD Million)

Table 32 Eastern Europe: Gestational Trophoblastic Disease Market, by Treatment, 2020–2027 (USD Million)

Table 33 Eastern Europe: Gestational Trophoblastic Disease Market, by End-User, 2020–2027 (USD Million)

Table 34 Eastern Europe: Gestational Trophoblastic Disease Market, by Region, 2020–2027 (USD Million)

Table 35 Asia-Pacific: Gestational Trophoblastic Disease Market, by Type, 2020–2027 (USD Million)

Table 36 Asia-Pacific: Gestational Trophoblastic Disease Market, by Treatment, 2020–2027 (USD Million)

Table 37 Asia-Pacific: Gestational Trophoblastic Disease Market, by End-User, 2020–2027 (USD Million)

Table 38 Asia-Pacific: Gestational Trophoblastic Disease Market, by Region, 2020–2027 (USD Million)

Table 39 Middle East & Africa: Gestational Trophoblastic Disease Market, by Type, 2020–2027 (USD Million)

Table 40 Middle East & Africa: Gestational Trophoblastic Disease Market, by Treatment, 2020–2027 (USD Million)

Table 41 Middle East & Africa: Gestational Trophoblastic Disease Market, by End-User, 2020–2027 (USD Million)

Table 42 Middle East & Africa: Gestational Trophoblastic Disease Market, by Region, 2020–2027 (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Gestational Trophoblastic Disease Market

Figure 3 Segmentation Market Dynamics for Global Gestational Trophoblastic Disease Market

Figure 4 Global Gestational Trophoblastic Disease Market Share, by Type, 2020 (%)

Figure 5 Global Gestational Trophoblastic Disease Market Share, by Treatment, 2020 (%)

Figure 6 Global Gestational Trophoblastic Disease Market Share, by End-User, 2020 (%)

Figure 7 Global Gestational Trophoblastic Disease Market Share, by Region, 2020 (%)

Figure 8 North America: Gestational Trophoblastic Disease Market Share, by Country, 2020 (%)

Figure 9 Europe: Gestational Trophoblastic Disease Market Share, by Country, 2020 (%)

Figure 10 Asia-Pacific: Gestational Trophoblastic Disease Market Share, by Country, 2020 (%)

Figure 11 Middle East & Africa: Gestational Trophoblastic Disease Market Share, by Country, 2020 (%)

Figure 12 Global Gestational Trophoblastic Disease Market: Company Share Analysis, 2020 (%)

Figure 13 Teva Pharmaceutical Industries Ltd.: Key Financials

Figure 14 Teva Pharmaceutical Industries Ltd.: Segmental Revenue

Figure 15 Teva Pharmaceutical Industries Ltd.: Geographical Revenue

Figure 16 Hikma Pharmaceuticals PLC: Key Financials

Figure 17 Hikma Pharmaceuticals PLC: Segmental Revenue

Figure 18 Hikma Pharmaceuticals PLC: Geographical Revenue

Figure 19 Pfizer Inc.: Key Financials

Figure 20 Pfizer Inc.: Segmental Revenue

Figure 21 Pfizer Inc.: Geographical Revenue

Figure 22 Bristol-Myers Squibb Company: Key Financials

Figure 23 Bristol-Myers Squibb Company: Segmental Revenue

Figure 24 Bristol-Myers Squibb Company: Geographical Revenue

Figure 25 Antares Pharma: Key Financials

Figure 26 Antares Pharma: Segmental Revenue

Figure 27 Antares Pharma: Geographical Revenue

Figure 28 Mylan N.V.: Key Financials

Figure 29 Mylan N.V.: Segmental Revenue

Figure 30 Mylan N.V.: Geographical Revenue

Figure 31 Novartis AG: Key Financials

Figure 32 Novartis AG: Segmental Revenue

Figure 33 Novartis AG: Geographical Revenue

Figure 34 BP Pharmaceuticals Laboratories Company: Key Financials

Figure 35 BP Pharmaceuticals Laboratories Company: Segmental Revenue

Figure 36 BP Pharmaceuticals Laboratories Company: Geographical Revenue

Figure 37 Fresenius Kabi AG: Key Financials

Figure 38 Fresenius Kabi AG: Segmental Revenue

Figure 39 Fresenius Kabi AG: Geographical Revenue

Figure 40 Accord Healthcare, Inc.: Key Financials

Figure 41 Accord Healthcare, Inc.: Segmental Revenue

Figure 42 Accord Healthcare, Inc.: Geographical Revenue

Figure 43 Eli Lilly and Company: Key Financials

Figure 44 Eli Lilly and Company: Segmental Revenue

Figure 45 Eli Lilly and Company: Geographical Revenue

Figure 46 Sanofi: Key Financials

Figure 47 Sanofi: Segmental Revenue

Figure 48 Sanofi: Geographical Revenue

Figure 49 Bayer AG: Key Financials

Figure 50 Bayer AG: Segmental Revenue

Figure 51 Bayer AG: Geographical Revenue

Figure 52 Amgen Inc.: Key Financials

Figure 53 Amgen Inc.: Segmental Revenue

Figure 54 Amgen Inc.: Geographical Revenue

Figure 55 Merck: Key Financials

Figure 56 Merck: Segmental Revenue

Figure 57 Merck: Geographical Revenue